What is the 13F Pro Quality Score for AYTU?

13F Pro ranks AYTU BIOPHARMA, INC (AYTU) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View AYTU's current score at https://13fpro.ai/research/AYTU (free sign-up required for the full ranking).

Where does 13F Pro source AYTU data?

All AYTU BIOPHARMA, INC fundamentals and ownership data come directly from SEC EDGAR. AYTU BIOPHARMA, INC files with the SEC under CIK 1385818. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is AYTU in?

AYTU BIOPHARMA, INC (AYTU) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is AYTU research updated on 13F Pro?

AYTU's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

AYTU BIOPHARMA, INC(AYTU)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1385818 AYTU stock profile & AI dashboard →

13F Pro Quality Score

21.5/100

Rank #2,656 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

16.3/100

Profitability

16.0/100

Balance Sheet

19.4/100

Earnings Quality

30.0/100

Free Cash Flow

17.2/100

Institutional Flow

62.3/100

Revenue Scale

12.8/100

Dilution Risk

61.0/100

AYTU Stock Analysis & AI Quality Score

AI stock analysis and institutional research for AYTU BIOPHARMA, INC (AYTU), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores AYTU at 21.5/100 on a 32-signal composite quality model, placing it at rank #2,656 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (12.8) and profitability (16.0), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q3 2026), AYTU BIOPHARMA, INC reports quarterly revenue of $12.4M, net income of $-5.6M, an operating margin of -32.8%. Top institutional holders of AYTU by reported 13-F value include Arete Wealth Advisors,, Nantahala Capital Management,, Stonepine Capital Management,, based on the most recent SEC filings. AYTU trades on the Nasdaq exchange and files with the SEC under CIK 1385818. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate AYTU daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AYTU BIOPHARMA, INC directly from SEC EDGAR. AYTU BIOPHARMA, INC's 13F Pro composite quality score has ranged between 16 and 43 since 2021, currently 21.5 — a declining long-term trajectory across 27 quarterly and live scoring snapshots.

✦

Fun facts about AYTU BIOPHARMA, INC

Quirks, history, and lore behind AYTU — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. specialty pharmaceutical company · listed on Nasdaq · focused on commercial-stage branded drugs · headquartered in Colorado.
2
The Numbers
A micro-cap with annual revenue in the range of tens of millions of dollars — small enough that a single product launch can move the whole needle.
3
The History
The company took its current form through a merger in 2020, combining two small pharma outfits to build a broader pediatric and men's health drug portfolio.
4
The Secret
Its commercial focus spans ADHD treatments, allergic rhinitis, and testosterone deficiency — an oddly specific trio that somehow makes strategic sense.
5
The Lore
One of its key products, Adzenys, is an extended-release, orally dissolving amphetamine tablet — basically ADHD medication that melts on your tongue like a tiny pharma breath strip.
6
The Giveaway
Its ticker spells out its identity almost literally: AYTU, short for a biopharma built around Adzenys XR-ODT and a handful of niche branded drugs targeting kids and men.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q3 2026

$12.4M

Net Income

Q3 2026

$-5.6M

Free Cash Flow

Q3 2026

$-4.2M

Operating Margin

Q3 2026

-32.8%

D/E Ratio

Q3 2026

0.38

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+1.8% YoY

$66.4MFY 2025

FY21 $65.6MFY22 $96.7MFY24 $65.2MFY25 $66.4M

Net Income

+14.4% YoY

$-13.6MFY 2025

FY21 $-58.3MFY22 $-108.8MFY24 $-15.8MFY25 $-13.6M

Operating Income

-392.0% YoY

$-7.8MFY 2025

FY21 $-58.9MFY22 $-109.9MFY24 $-1.6MFY25 $-7.8M

EPS (Diluted)

—FY 2025

FY21 $-3.48FY22 $-74.01FY24 —FY25 —

Total Assets

+5.2% YoY

$124.2MFY 2025

FY21 $265.7MFY22 $137.6MFY24 $118.1MFY25 $124.2M

Total Debt

-14.0% YoY

$14.6MFY 2025

FY21 $16.8MFY22 $18.9MFY24 $17.0MFY25 $14.6M

Op. Cash Flow

-39.6% YoY

$-1.9MFY 2025

FY21 $-26.0MFY22 $-28.8MFY24 $-1.4MFY25 $-1.9M

Metric	FY 2025	FY 2024	FY 2022	FY 2021	FY 2020	FY 2019
Revenue	$66.4M +1.8%	$65.2M -32.6%	$96.7M +47.3%	$65.6M +137.5%	$27.6M +277.5%	$7.3M
Net Income	$-13.6M +14.4%	$-15.8M +85.4%	$-108.8M -86.6%	$-58.3M -327.9%	$-13.6M +49.8%	$-27.1M
Operating Income	$-7.8M -392.0%	$-1.6M +98.6%	$-109.9M -86.7%	$-58.9M -178.6%	$-21.1M -25.4%	$-16.8M
EPS (Diluted)	—	—	$-74.01 -2026.7%	$-3.48	—	—
Total Assets	$124.2M +5.2%	$118.1M -14.2%	$137.6M -48.2%	$265.7M +73.3%	$153.3M +341.5%	$34.7M
Total Debt	$14.6M -14.0%	$17.0M -10.2%	$18.9M +12.2%	$16.8M +757.8%	$2.0M	$0.00
Operating Cash Flow	$-1.9M -39.6%	$-1.4M +95.2%	$-28.8M -11.0%	$-26.0M +8.5%	$-28.4M -105.1%	$-13.8M

AI Insight: AYTU Financial Trends

Revenue collapsed 33% from Q1 2025 peak to Q1 2026, while net losses have resumed and operating cash flow turned negative.

• Revenue declined from $18M in Q1 2025 to $12M in Q1 2026, a 33% contraction over four quarters.

• Net income swung from $4M profit in Q1 2025 to $-6M loss in Q1 2026; four of last eight quarters show losses.

• Total debt stabilized at $13–14M since Q3 2025, while equity recovered to $35M in Q1 2026 from $14M low.

⚠ Operating cash flow turned negative at -$4M in Q1 2026 after three consecutive profitable quarters.

⚠ Q1 2025 marked inflection point with $18M revenue and $2M operating income; all subsequent quarters show deterioration.

AI Insight: AYTU Ratio Trends

AYTU swung from Q1 2025 profitability (OpMargin +13.1%, NPM +21.6%) to sustained losses across the trailing twelve months, with operating margin collapsing to -26.8%.

• Q1 2025 marked a turnaround quarter with operating margin +13.1%, NPM +21.6%, and ROIC +20.1%; all metrics deteriorated sharply thereafter.

• TTM operating margin stands at -26.8% and NPM at -60.2%, reflecting a return to sustained unprofitability in recent quarters.

• Leverage increased: D/E rose to 0.97 in Q4 2025 before dropping to 0.38 in Q1 2026, suggesting balance-sheet volatility.

⚠ Q2 2025 was catastrophic: OpMargin -50.4%, NPM -130.9%, ROA -63.8%, ROIC -90.8%. Investigate underlying cause and recurrence risk.

⚠ ROIC remained negative for 6 of last 9 quarters; only Q3 2024 and Q1 2025 turned positive. Sustainability of any profit inflection unclear.

Get alerted when AYTU's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for AYTU BIOPHARMA, INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of AYTU

Arete Wealth Advisors, LLC
$4.0M49,549 sh
Nantahala Capital Management, LLC
$3.0M1,086,812 sh
Stonepine Capital Management, LLC
$2.2M792,289 sh
AWM Investment Company, Inc.
$1.7M619,574 sh
DIADEMA PARTNERS LP
$963.9K353,077 sh
VANGUARD CAPITAL MANAGEMENT LLC
$712.9K261,146 sh
TWO SIGMA INVESTMENTS, LP
$333.0K121,973 sh
RENAISSANCE TECHNOLOGIES LLC
$255.9K93,723 sh
Persistent Asset Partners Ltd
$253.6K92,897 sh
GEODE CAPITAL MANAGEMENT, LLC
$252.9K92,636 sh

Fund	Value	Shares
Arete Wealth Advisors, LLC	$4.0M	49,549
Nantahala Capital Management, LLC	$3.0M	1,086,812
Stonepine Capital Management, LLC	$2.2M	792,289
AWM Investment Company, Inc.	$1.7M	619,574
DIADEMA PARTNERS LP	$963.9K	353,077
VANGUARD CAPITAL MANAGEMENT LLC	$712.9K	261,146
TWO SIGMA INVESTMENTS, LP	$333.0K	121,973
RENAISSANCE TECHNOLOGIES LLC	$255.9K	93,723
Persistent Asset Partners Ltd	$253.6K	92,897
GEODE CAPITAL MANAGEMENT, LLC	$252.9K	92,636

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put AYTU on your watchlist

Track score changes the day AYTU BIOPHARMA, INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is AYTU a good stock to buy?

13F Pro's AI-powered analysis of AYTU BIOPHARMA, INC (AYTU) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for AYTU are available on the AYTU stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own AYTU?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling AYTU. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AYTU BIOPHARMA, INC's investment landscape.